The role of human papillomaviruses in cancer progression

Tulay, Pınar; Serakıncı, Nedime

doi:10.20517/2394-4722.2015.67

Cited by 38 publications

(26 citation statements)

References 172 publications

(215 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of HPV in carcinogenesis process and progression has been already proven. 7,8 Molecular data suggest that E6 and E7, two transforming proteins encoded by HPV-HR, interfere of several biomarkers of cell proliferation and apoptosis including p53, p16 7,9 survivin and IGF-1R. 10,11 The expression profile of p16 and survivin markers and their prognostic value have been previously assessed on Tunisian patients with laryngeal cancer.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Prognostic Value of HPV among Tunisian Patients with Laryngeal Cancer and Relationship between DNA HPV and p16, IGF-1R, Survivin, p53 Expressions

Elhadj

Fourati

Amine

et al. 2020

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

Objectives: Tobacco and alcohol are the main etiological factors common to laryngeal cancers. However, the Human Papilloma Virus (HPV) constitutes an alternative risk factor according to several studies. In Tunisia, despite the annual increasing incidence of laryngeal squamous cell carcinoma (LSCC), the prevalence and prognostic significance of HPV have never been explored. In this study, we sought to highlight HPV DNA in 70 biopsies of laryngeal cancer, and to analyze the status of HPV infection in association with p53, p16, survivin, and IGF-1R expressions. Methods: HPV high risk (HPV HR) DNA was detected in tumors by in situ hybridization. However, the expression of p53, p16, survivin and IGF-1R were stained by immunohistochemistry test. The correlations of HPV status with clinicopathological parameters, overall survival, disease-free survival and proteins expressions were statistically evaluated. Results: HPV HR DNA was detected in 39 out of 70 (55.71%) laryngeal tumors. HPV+ patients have a better overall survival ( P = .081) and long disease-free-survival ( P = .016) with a low rate of recurrence ( P = .006) than HPV– patients. No significant correlations were found between HPV HR status and clinicopathological parameters (all P > .005). Moreover, HPV+ tumors were not associated with expression of p53, p16 and survivin. However, HPV HR status correlates with weak to moderate IGF-1R expression ( P = .043). Conclusion: The substantial detection of HPV HR in LSCC tumors suggest that this virus plays an important part in laryngeal cancer in Tunisia. It is a good prognostic factor. In addition, HPV infection could act to block the pathway of IGF-1R expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and Prognostic Value of HPV among Tunisian Patients with Laryngeal Cancer and Relationship between DNA HPV and p16, IGF-1R, Survivin, p53 Expressions

Elhadj

Fourati

Amine

et al. 2020

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

show abstract

“…Global HPV infections are associated with an estimated 50% of cancers in women and 5% in men, with varying burden depending on anatomical site. Anogenital sites are more significantly affected with proportions of more than 99% of cervical, 97% of anal, 70% of vaginal, 47% of penile and 40% of vulval cancer cases, compared to 47% of oropharynx and 11% of oral cavity cancer cases [8]. HPV types 16 and 18 account for more than 70% of invasive cervical carcinoma (ICC), the most significant cancer caused by the HPV [9].…”

Section: Introductionmentioning

confidence: 99%

Implementation strategy and cost of Mozambique’s HPV vaccine demonstration project

et al. 2019

View full text Add to dashboard Cite

BackgroundCost is an important determinant of health program implementation. In this study, we conducted a comprehensive evaluation of the implementation strategy of Mozambique’s school-based HPV vaccine demonstration project. We sought to estimate the total costs for the program, cost per fully immunized girl (FIG), and compute projections for the total cost of implementing a similar national level vaccination program.MethodsWe collected primary data through document review, participatory observation, and key informant interviews at all levels of the national health system and Ministry of Education. We used a combination of micro-costing methods—identification and measurement of resource quantities and valuation by application of unit costs, and gross costing—for consideration of resource bundles as they apply to the number of vaccinated girls. We extrapolated the cost per FIG to the HPV-vaccine-eligible population of Mozambique, to demonstrate the projected total annual cost for two scenarios of a similarly executed HPV vaccine program.ResultsThe total cost of the Mozambique HPV vaccine demonstration project was $523,602. The mean cost per FIG was $72 (Credibility Intervals (CI): $62 - $83) in year one, $38 (CI: $37 - $40) in year two, and $54 CI: $49 - $61) for years one and two. The mean cost per FIG with the third HPV vaccine dose excluded from consideration was $60 (CI: $50 - $72) in year one, $38 (CI: $31 - $46) in year two, and $48 (CI: $42 - $55) for years one and two. The mean cost per FIG when only one HPV vaccine dose is considered was $30 (CI: $27 - $33)) in year one, $19 (CI: $15–$23) in year two, and $24 (CI: $22–$27) for both years. The projected annual cost of a two-and one-dose vaccine program targeting all 10-year-old girls in the country was $18.2 m (CI: $15.9 m - $20.7 m) and $9 m (CI: $8 m - $10 m) respectively.ConclusionNational adaptation and scale-up of Mozambique’s school-based HPV vaccine strategy may result in substantial costs depending on dosing. For sustainability, stakeholders will need to negotiate vaccine price and achieve higher efficiency in startup activities and demand creation.

show abstract

“…It is well reported the importance of HPV infection in different type of benign and malignant tumors. It is well established that there is association between HPVs with cervical cancer [29]. Moreover, environmental pollutions associated with conflicts may be another source for increase cancer related cases [5].…”

Section: Introductionmentioning

confidence: 99%

Gold Nanoparticles Targeting Human Cervical Cancer Cells

Merkadh¹,

Hameed²

2019

SIJOG

View full text Add to dashboard Cite

The most disturbing gynecologic malignancies are cervical cancer particularly in the developing world with the same high incidence in Iraqi women. Cervical carcinoma has a high rate of mortality. The high death rate is associated with presence of human papillomavirus (HPV) infection. Cervical carcinoma is hard to treat, and conventional therapies are very aggressive which lead for the need for new approaches of therapy. Nanoparticles is a promising treatment modality to produce non-toxic and efficient cancer therapy. Gold nanoparticles (AuNPs) accumulate in cancer cells selectively. The current work was aimed to study cytotoxicity and cell death induced by AuNPs on cervical carcinoma cells. Methods: Cytotoxicity of AuNPs was assessed by MTT viability assay and analysed using multiple comparison ANOVA tests. Results: AuNPs nanoparticles from 12.5 up to 50 µg/mL for 72 hours showed concentration-dependent killing activity. Conclusion: Gold nanoparticles have anti-cervical carcinoma cells activity by cell death induction.

show abstract

The role of human papillomaviruses in cancer progression

Cited by 38 publications

References 172 publications

Prevalence and Prognostic Value of HPV among Tunisian Patients with Laryngeal Cancer and Relationship between DNA HPV and p16, IGF-1R, Survivin, p53 Expressions

Prevalence and Prognostic Value of HPV among Tunisian Patients with Laryngeal Cancer and Relationship between DNA HPV and p16, IGF-1R, Survivin, p53 Expressions

Implementation strategy and cost of Mozambique’s HPV vaccine demonstration project

Gold Nanoparticles Targeting Human Cervical Cancer Cells

Contact Info

Product

Resources

About